Apitope is a European biotech company focusing on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease.
The Company is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system.
Apitope was founded in 2002 by world renowned immunologist, Professor David Wraith and Angel investor, Richard Daniels. It has a highly experienced management team, with a proven track record in discovering and developing innovative therapeutics. It has built up an impressive pipeline based on its leading edge technology platform. Apitope’s lead product candidate is under investigation for the potential treatment of multiple sclerosis. It is currently in Phase I development and is partnered with Merck-Serono... more >>
About Apitope
Latest
Latest Clinical Trial
Apitope is developing ATX-MS-1467, a disease-modifying therapy for treating MS... more >>
Current Openings
Research Scientist(s) – Immunology... more>>
“Therapeutics to halt autoimmune disease progression”
News
Apitope signed an agreement in 2009 with Merck Serono valued up to EUR154 million for the development and commercialisation of ATX-MS-1467... more>>
Product Pipeline
Apitope has built up an impressive pipeline of therapeutics and diagnostics. Apitope’s lead product is ATX-MS-1467, a disease-modifying therapy for treating MS. ATX-MS-1467 is a novel peptide-based therapeutic derived from Apitope’s proprietary technology platform. It is designed to target up to.more>>
Research & Development
Apitope is developing innovative therapeutic peptides for the effective treatment of autoimmune and allergic diseases. These first-in-class compounds treat the disease rather than treating disease symptoms or non-specifically suppressing the immune system which... more>>
